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Abstract
AIM: To evaluate the potential association of xeroderma 
pigmentosum group D (XPD) codon 751 variant with 
outcome after chemo-radiotherapy in patients with 
resected gastric cancer.
METHODS: We used PCR-RFLP to evaluate the genetic 
XPD Lys751Gln  polymorphisms in 44 patients with stage 
Ⅲ (48%) and Ⅳ (20%) gastric cancer treated with 
surgery following radiation therapy plus 5-fluorouracil/
leucovorin based chemotherapy.
RESULTS: Statistical analysis showed that 75% (12 of 
16) of relapse patients showed Lys /Lys  genotype more 
frequently (P  = 0.042). The Lys  polymorphism was an 
independent predictor of high-risk relapse-free survival 
from Cox analysis (HR: 3.07, 95% CI: 1.07-8.78, P  = 
0.036) and Kaplan-Meir test (P  = 0.027, log-rank test). 
CONCLUSION: XPD Lys751Gln  polymorphism may be 
an important marker in the prediction of clinical outcome 
to chemo-radiotherapy in resected gastric cancer 
patients.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
The xeroderma pigmentosum group D (XPD) gene en-
codes a protein required for nucleotide excision repair 
(NER). This product recognizes and repairs a wide range 
of  structurally unrelated lesions such as bulky adducts 
caused by UV light, environmental agents, cross links and 
oxidative damage[1,2]. Moreover, XPD gene is one of  the 
components of  basal transcription factor IIH (TFIIH), 
participating also in transcription initiation. Since XPD is 
involved in both transcription and NER, it may be able to 
repair other types of  damage, such as radiation therapy-in-
duced damage. Because XPD interacts with many different 
proteins as part of  TFIIH transcription factor, amino acid 
variants in different domains of  XPD, such as 683 and 
751, may affect different protein interactions, and result in 
expression of  different phenotypes[3,4].
Intrinsic and acquired resistance to cancer chemo-
therapeutic agents results from polymorphisms in genes 
encoding DNA repair enzymes. Differences in responsive-
ness of  cancer cells to anticancer agents can be differently 
affected by changes in repair effi ciency. Clinical outcomes 
after chemotherapy may be infl uenced by pharmacogenetic 
polymorphisms in DNA repair enzymes. In this sense, 
three single nucleotide polymorphisms (SNP) in the XPD 
gene (in codons 156, 312, and 751) are related with dif-
ferent DNA repair capacity[5-7]. Thus, variants generated 
by amino acids can change Asp312Asn (exon 10, G > A 
substitution) and Lys751Gln (exon 23 A > C substitution) 
located in conserved regions of  the XPD protein, and are 
associated with lower effi ciency of  damage repair and sig-
nifi cantly higher background frequency of  apoptotic cells 
in irradiated lymphocytes[8].
Although gastrectomy is the only potentially curative 
treatment in gastric-cancer patients, the overall survival 
results remain unsatisfactory. The main factor accounting 
for high mortality is relapse after surgical resection. During 
the past few decades, the principle of  combined treatment 
modality has been developed and applied in various solid 
tumors including gastric cancer. In order to prevent recur-
rence and increase the cure rate of  gastric-cancer after 
surgery, multiple studies using variable treatment modali-
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ties have been undertaken. One of  the landmark studies 
reported that chemo-radiotherapy can significantly im-
prove survival after resection of  stage IB to stage Ⅳ gas-
tric cancers[9]. Chemo-radiotherapy has been increasingly 
recognized as a standard of  care since then[10,11]. However, 
whether adjuvant chemo-radiotherapy can prolong the 
survival of  patients with extensive lymph node dissec-
tion remains debatable. In this paper, we evaluated the 
potential role of  XPD codon 751 variant in the outcome 
of  44 patients with resected gastric cancer after chemo-
radiotherapy.
PATIENTS AND METHODS
Patients
Characteristics of  the patients are listed in Table 1. From 
October 1992 to January 1999, 44 patients consisting of  
32 men (73%) and 12 women (27%) with a median age of  
60 years (range: 33-77 years) with diagnosis of  gastric can-
cer after having undergone gastrectomy were treated with 
radiation plus 5-fl uorouracil (5-FU) and leucovorin. Thirty-
two percent of  the patients had stageⅠ-Ⅱand 68% stage 
Ⅲ-Ⅳ gastric cancer at the time of  diagnosis (Table 1). The 
median follow-up time was 46.9 mo (range: 5.33 to 124.06 
mo). The median time to progression was 37.5 mo (range: 
2.3 to 95.4 mo). This study was conducted in Navarra 
Hospital Center, and informed consent was obtained from 
all the patients for using their tissues. The clinicopatho-
logical information of  each subject was obtained from the 
tumor registry at Navarra Hospital. 
Treatment schedule
The patients received postoperative treatment with 5-FU 
plus leucovorin and local radiation 20-40 d after gastrec-
tomy. This chemotherapy regimen developed by the North 
Central Cancer Treatment Group[12] was used before and 
after radiation. Chemotherapy (fluorouracil, 425 mg/m2 
per day, and leucovorin, 20 mg/m2 per day) was initiated 
on d 1 followed by chemo-radiotherapy on d 28 after the 
initial cycle of  chemotherapy. Chemo-radiotherapy con-
sisted of  4500 cGy of  radiation at 180 cGy/d, 5 d/wk for 
5 wk, with 5-FU (400 mg/m2 per day) and leucovorin (20 
mg/m2 per day) on the fi rst four and the last three days of  
radiotherapy. One month after radiotherapy, two 5-d cycles 
of  5-FU (425 mg/m2 per day) plus leucovorin (20 mg/m2 
per day) were given every other month.
The 4500 cGy of  radiation was delivered in 25 frac-
tions (5 d/wk) to the tumor bed, regional nodes and 2 
cm beyond the proximal and distal margins of  resection. 
The adjuvant treatment was performed as previously de-
scribed[9]. 
Samples and DNA extraction
Surgical specimens (paraffi n blocks) were cut into 5 μm-
thick sections for molecular analysis. 
Three tissue sections were transferred into a micro 
centrifuge tube and 1.2 mL of  xylene was added. After 
centrifugation at 14 000 r/min for 5 min at room temper-
ature (RT), the supernatant was removed. Subsequently, 
the tissue samples were washed in 1.2 mL of  96 mL/L 
ethanol. After centrifugation at 14 000 r/min for 5 min at 
RT, the supernatant was discarded. The washing proce-
dure was repeated another time. The samples were dried 
for 3-5 min, in a vacuum pump (any letter between were 
and dried).
DNA was extracted using the QIAamp DNA Mini Kit 
(Qiagen-IZASA- Barcelona Spain). The deparaffinized 
samples were re-suspended in 180 μL of  ATL buffer 
plus 20 μL of  proteinase K and incubated overnight 
at 56℃. The samples were processed according to the 
provided protocol. The purified DNA was finally eluted 
in a total volume of  150 μL. DNA yield was quantifi ed by 
NanoDrop 3.0.0 (Nucliber, Wilmington, Delaware USA).
About 7-509 mg/L of  DNA was extracted and 45-200 
ng of  genomic DNA was used as template. PCR/RFLP-
based assays were performed as described previously[5] 
with slight modifi cations. The PCR product (20 μL) was 
digested with 25 units of  Pst I enzyme (New England 
BioLabs, -IZASA, S.A, Barcelona-, Spain) in 50 μL 
reaction mixture for 1 h. The digestion product was 
visualized in 3% agarose gel (Pronadisa, Madrid, Spain). 
The wild-type homozygote was defined by 104- and 
220-bp banding patterns; the heterozygote by 63-, 104-, 
157-, and 220-bp fragments; and variant homozygote 
Table 1  Characteristics of the patients
Baseline factors                        n  (%)
Sex
   Male 32 (73)
   Female 12 (27)
Age (yr)
   ≤ 50 16 (36)
    51-64 13 (30)
   ≥ 65 15 (34)
   Median (Range) 60 (33-77)
Stage at diagnostic
   Ⅰ-Ⅱ 14 (32)
   ⅢA + ⅢB 21 (48)
   Ⅳ   9 (20)
Histotype
   Intestinal   9 (20)
   Diffuse 35 (80)
Grading
  Ⅰ   3 (7)
  Ⅱ   8 (18)
  Ⅲ 33 (75)
Tumor location
   Cardia   9 (21)
   Fundus   9 (21)
   Body 10 (24)
   Antrum 14 (33)
Gastrectomy
   R0 35 (80)
   R1   8 (18)
   R2   1 (2)
XPD 751
   Lys/Lys 19 (51)
   Lys/Gln 14 (38)
   Gln/Gln   4 (11)
   Unknown   7
by 63-, 104-, and 157-bp fragments. Some samples 
were noted as “unknown” because they could not be 
amplifi ed due to a relatively frequent occurrence of  PCR 
inhibitory substances in samples prepared with this DNA 
extraction method (Table 1). Furthermore, three DNA 
samples corresponding to each genotype selected by direct 
sequencing were used. The results were in concordance 
with RFLP genotyping.
Statistical analysis
This study was designed to analyze the role of  XPD 
polymorphism in the prediction of  relapse. Relapse free-
survival (RFS) was defi ned as the time from the start of  
chemotherapy to the first evidence of  disease progres-
sion. RFS was calculated using the Kaplan-Meier method. 
Contingency tables and chi-square test (χ2) were used to 
summarize the association of  relapse with XPD poly-
morphism. All P values were two-sided. Cox proportional 
hazards models were also used to evaluate the different 
variables considered. All statistical tests were conducted by 
SPSS software 11.0 version for Windows (SPSS, Inc. Chi-
cago). P ≤ 0.05 was considered statistically signifi cant.
RESULTS
Thirty-seven patients were evaluated for the Lys751Gln 
polymorphism. Seven patient were not assessed due to 
poor sample extraction quality. Fifty-one percent (19 of  
37) of  the patients were homozygous for the Lys/Lys 
genotype, 38% (14/37) heterozygous for Lys/Gln, and 
11% (4 of  37) homozygous for the glutamine variant (Table 
1). The 751Gln allele frequency was 0.33, similar to that 
observed in other studies[5,7].
Sixteen patients (36%) developed grade Ⅲ-Ⅳ toxicity. 
Hematological toxicity was found in 62% (10/16) 
patients compared with gastrointestinal and other toxicity 
in19% (3/16) patients (Table 2). However, there was no 
association between XPD genotype and toxicity (data not 
shown).
Gastrectomy with D1 lymphadenectomy was per-
formed in all patients. Of  the 44 patients, 20 (45.5%) had 
relapse and 17 (85%) of  them died. The fi rst relapse site 
was local in 5, distant in 10, and both local and distant in 5 
(Table 3).
Statistical analysis showed that 75% (12 of  16) of  re-
lapse patients showed Lys/Lys genotype more frequently (P 
= 0.042, Table 4).
Other clinico-pathological features such as histology, 
grading and localization were not significant (data not 
shown).
The relative risk of  progression (with Lys/Lys genotype 
used as the reference) was 0.35 (95% CI: 0.11-1.09) for 
patients carrying the Lys/Gln genotype and 0.25 (95% CI: 
0.03-1.96) for the Gln/Gln group (Table 5).
Only XPD genotype and stage to diagnosis showed a 
signifi cant relation with cancer relapse and were evaluated 
as potential predictors of  RFS by Cox test. We used the 
combined genotypes LysGln/GlnGln as reference in these 
analyses and found that the Lys/Lys genotype was more 
strongly associated with disease progression (P = 0.036) 
than the combined LysGln/GlnGln genotype (adjusted HR: 
3.07, 95% CI: 1.07-8.78) (Table 6, Figure 1). 
DISCUSSION
Most cases of  gastric cancer are diagnosed at an advanced 
stage with poor prognosis. Surgery remains the only 
potentially curative treatment, but it is associated with a 
high rate of  local recurrence and distant metastases. When 
irradiation is combined with surgical resection for all or a 
Table 2  Toxicity evaluated
Toxicity grade Ⅲ-Ⅳ                          n  (%)
No 28 (64)
Yes 16 (36)
   Toxicity type
      Hematological 10 (62)
      Digestive   3 (19)
      Others   3 (19)
Table 3  Relapse site
Relapse                                          n  (%)
No 24 (54.5)
Yes 20 (45.5)
Relapse sites
   Local   5 (25)
   Distant 10 (50)
   Local + Distant   5 (25)
Table 4  Results of chi-square test for disease relapse
Relapse               XPD                            Stage
Lys Lys/Gln Gln/Gln Ⅰ+ Ⅱ ⅢA + ⅢB + Ⅳ
No   7     11       3     11             13
Yes 12       3       1       3             17
  P                      0.042                                     0.050
Table 5  Unadjusted XPD genotype and relapse-free survival 
(RFS)
XPD          RFS (median)    Hazard Ratio       95% CI
Lys/Lys 11.79 1.0 Reference
Lys/Gln 14.33 0.35 0.11 to 1.09
Gln/Gln 23.33 0.25 0.03 to 1.96
Table 6  Adjusted Cox multivariate analysis for RFS
XPD              RFS (median)   Hazard ratio        95% CI          P
Lys/Lys 11.79 3.07 1.07 to 8.78
0.036Lys/Gln + Gln/Gln 20.26 1.0 Reference
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majority of  tumors, both survival and local control appear 
to be better than those for the unresected patients[13]. 
Epidemiological studies have shown that Gln variant at 
XPD-751 polymorphism is partiality able to repair DNA 
in lung cancer[7,14]. In this sense, cancer treatment is to 
cause DNA damage and tumor cell apoptosis. Gln variant 
seems to show a lower ability to repair DNA damage and 
cancer patients are more sensitive to chemo-radiotherapy. 
In contrast, the presence of  allele Lys represents a 
positive effect in different DNA repair pathways and 
a possible poor response to cancer treatment. In this 
study, we found a signifi cant relationship between clinical 
response to chemo-radiotherapy and the XPD Lys751Gln 
polymorphism. Patients with the Lys/Lys genotype were 
more likely to have relapse compared to those with the 
combined Lys/Gln and Gln/Gln genotype.
Scientifi c publications are available but with diverging 
results in the XPD751 polymorphism and cancer risk or 
treatment effi ciency[3,5-7]. Thus, decreased DNA repair has 
been associated with Lys allele[6]. Epidemiological study has 
reported association of  this allele with a higher risk of  ba-
sal cell carcinoma[5] even though no signifi cant relationship 
between this polymorphic gene and DNA repair profi cien-
cy has been reported[15,16]. Spitz et al[7] and other research 
group[17] reported a suboptimal DNA repair capacity (DRC) 
particularly in subjects who were homozygous for 751Gln 
alleles. Moreover, a recently study has found a tendency to-
ward a higher background frequency of  apoptotic cells in 
irradiated lymphocytes carrying variant homozygote Gln at 
XPD codon 751[8]. Our results are in agreement with these 
studies, suggesting that heterozygote and homozygote Gln 
alleles may therefore increase their clinical response to 
suboptimal DNA damage repair after treatment. 
Repair of  DNA damage is a complex process[1,18,19]. 
Functional protein of  XPD could be affected by a struc-
tural change (Lys → Gln) from a basic to a polar amino 
acid change located at about 50-base upstream from the 
poly (A) signal[5]. Moreover, close proximity in the genome 
between XPD and other polymorphic DNA repair genes 
such as X-ray repair cross complementing (XRCC1) and 
excision repair cross complementing (ERCC1) may infl u-
ence the interaction between them leading to different 
or synergic DNA repair capability. A recent molecular 
epidemiology study has genotyped 44 SNPs in 20 genes 
involved in four DNA damage repair pathways, showing 
that homozygous Gln751Gln and other gene variants geno-
typed are highly associated with lung cancer risk[20]. In the 
same way, variant Gln allele and some nucleotide and base 
excision repair (NER and BER, respectively) variant gene 
members are associated with increased level of  polycyclic 
aromatic hydrocarbon-DNA adducts[15,21]. 
In conclusion, XPD Lys751Gln polymorphism may be 
an important marker of  genotoxicity that can predict the 
clinical outcome of  resected gastric cancer treated with 
chemo-radiotherapy.
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